Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNX201-ADC
- Development stage
- Preclinical
- Lead developer
- GlycoNex
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GNX201-ADC is a next-generation antibody-drug conjugate (ADC) developed by GlycoNex in collaboration with PrecisemAb Biotech. It utilizes a "Pro-Antibody" or "Antibody Lock" platform where the antibody's variable region is fused to a masking peptide via a protease-cleavable linker. This design ensures the drug remains inactive in systemic circulation, minimizing off-target toxicity. Upon reaching the tumor microenvironment, overexpressed proteases cleave the linker, "turning on" the antibody to selectively bind tumor-associated glycan antigens (TACA). Once activated and bound, the ADC delivers a potent cytotoxic payload directly to the cancer cells. It is currently in preclinical development for the treatment of various solid tumors.
- Other names
- anti-TACA pro-antibody ADCGNX201 pro-antibodyGNX-201 pro-antibodyGNX 201 pro-antibody
02
Targets
OAcGD2 (O-acetyl-GD2)
Beyond the preview
Go deeper on GNX201-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNX201-ADC.